KRAS 変異を有するさまざまな種類の進行がん患者を対象に、さまざまな用量の BI 1823911 を単独で、および他の医薬品と組み合わせてテストする研究
第 Ia/Ib 相、非盲検、多施設での用量漸増および拡大試験で、進行性または転移性固形腫瘍を発現している患者を対象に、BI 1823911 の単剤療法および他の抗がん療法との併用療法の安全性、薬物動態および予備的有効性を調査します。 KRAS G12C変異
This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful or no treatment exists.
People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes tumours grow faster. BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way. In this study, BI 1823911 is given to people for the first time.
The purpose of this study is to find the highest dose of BI 1823911 that people can tolerate when taken alone and together with BI 1701963. The most suitable dose is used to find out whether BI 1823911 alone and in combination with BI 1701963 can make tumours shrink.
Participants can stay in the study as long as they benefit from treatment and can tolerate it.
During this time, participants take tablets of BI 1823911 alone or in combination with BI 1701963 once a day. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participant's health.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10021
- Memorial Sloan-Kettering Cancer Center
-
-
Texas
-
Dallas、Texas、アメリカ、75230
- Sarah Cannon Research Institute at Mary Crowley
-
Houston、Texas、アメリカ、77030
- The University of Texas MD Anderson Cancer Center
-
-
-
-
-
Manchester、イギリス、M20 4BX
- The Christie
-
-
-
-
-
Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
-
Anderlecht/Brussels-Capital、ベルギー、1070
- Brussels - HOSP Jules Bordet
-
Edegem/Antwerpen、ベルギー、2650
- Universitair Ziekenhuis Antwerpen
-
Gent/Oost-Vlaanderen、ベルギー、9000
- Universitair Ziekenhuis Gent
-
Leuven/Vlaams-Brabant、ベルギー、3000
- UZ Leuven
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Pathologically confirmed diagnosis of locally advanced or metastatic solid tumours, e.g. adenocarcinoma of the lung, colorectal cancer, pancreatic cancer or cholangiocarcinoma. Non-small cell lung cancer (NSCLC) patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
-
Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage.
-
KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a validated test.
-
Provision of archival tumour tissue, if available, to confirm retrospectively KRAS G12C mutation status and for biomarker assessment.
-
At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (radiated lesions do not qualify as target lesions). In patients who only have one target lesion, and a biopsy of the lesion is required, the baseline imaging must be performed before the biopsy or at the earliest two weeks after the biopsy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Adequate organ function as follows:
- Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (equivalent values: ≥ 1.5 x 10³/μL or ≥ 1500/mm³); hemoglobin ≥9.0 g/dL (equivalent values: ≥ 90 g/L or ≥ 5.6 mmol/L); platelets ≥100 x 10^9/L (equivalent values: ≥ 100 x 10³/μL or ≥ 100 x 10³/mm³) without the use of haematopoietic growth factors.
- Total bilirubin ≤1.5 times the upper limit of normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome.
- Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥50 mL/min (equivalent value: 0.84mL/s) (measured or calculated by Cockcroft-Gault formula).
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN, for patients with liver metastases ≤5 x ULN.
-
Age ≥18 years of age, or over the legal age of consent as required by local legislation.
Further inclusion criteria apply.
Exclusion Criteria:
- Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment or anticancer immunotherapy within 2 weeks of the first administration of trial drug.
- Previous treatment with Rat Sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or Son of sevenless 1 (SOS1) targeting agents (only for monotherapy Parts A, B, and C).
- Radiotherapy within 2 weeks prior to start of treatment, provided recovery from related toxicity.
- Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement.
- Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment or 5 half-lives, whichever is shorter.
- Known history of hypersensitivity to any of the excipients of BI 1823911 tablets, or any contraindication to Midazolam (for Monotherapy Part B only).
- History or presence of cardiovascular abnormalities such as congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered clinically relevant by the Investigator. Myocardial infarction within 6 months prior to start of treatment. Uncontrolled hypertension defined as: Blood pressure (BP) measured in a rested and relaxed condition, where systolic BP >=140 mmHg, or diastolic BP >= 90 mmHg, with or without medication.
- Left ventricular ejection fraction (LVEF) <50%. Further exclusion criteria apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Monotherapy Arm
Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm |
|
実験的:Combination Therapy Arm
Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 BI 1701963 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination
時間枠:up to 28 days
|
DLTs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
up to 28 days
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR) defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR)
時間枠:up to 39 months
|
BOR is determined according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
用量漸増 (パート A) - 単剤療法および併用療法: BI 1823911 の全治療サイクル中に単剤療法および各併用療法で DLT を経験した患者の数
時間枠:39ヶ月まで
|
39ヶ月まで
|
|
|
全試験パート:治療期間中に有害事象が発生した患者数
時間枠:39ヶ月まで
|
39ヶ月まで
|
|
|
全試験パート、BI 1823911: 最大濃度 (Cmax)
時間枠:24時間まで
|
24時間まで
|
|
|
すべてのスタディ パーツ、BI 1823911: 定常状態濃度 (Css)
時間枠:24時間まで
|
24時間まで
|
|
|
全試験パート、BI 1823911: 時間ゼロから時間 t までの血漿濃度-時間曲線下の面積 (AUCτ)
時間枠:24時間まで
|
24時間まで
|
|
|
全試験パート、BI 1823911: 定常状態での血漿濃度-時間曲線下面積 (AUCss)
時間枠:24時間まで
|
24時間まで
|
|
|
全試験パート、BI 1701963: 最大濃度 (Cmax)
時間枠:24時間まで
|
24時間まで
|
|
|
すべてのスタディ パーツ、BI 1701963: 定常状態濃度 (Css)
時間枠:24時間まで
|
24時間まで
|
|
|
全試験パート、BI 1701963: 時間ゼロから時間 t までの血漿濃度-時間曲線下の面積 (AUCτ)
時間枠:24時間まで
|
24時間まで
|
|
|
全試験パート、BI 1701963: 定常状態での血漿濃度-時間曲線下面積 (AUCss)
時間枠:24時間まで
|
24時間まで
|
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR)
時間枠:up to 39 months
|
OR is defined as best overall response (BOR) of complete response (CR) or partial response (PR), both regardless of confirmation. BOR is determined according to RECIST version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Duration of OR
時間枠:up to 39 months
|
Duration of OR is defined as the time from first documented CR or PR until disease progression or death (whichever occurs first) among patients with OR. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Tumour shrinkage (in millimetres)
時間枠:up to 39 months
|
Tumour shrinkage is defined as the difference between the minimum post-baseline sum of diameters of target lesions (longest for non-nodal lesions, short axis for nodal lesions) and the baseline sum of longest diameters of the same set of target lesions. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Progression-free survival (PFS) rate
時間枠:at month 6
|
PFS is defined as the time from first treatment administration until tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs earlier. |
at month 6
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 1472-0001
- 2021-000460-29 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。